Spots Global Cancer Trial Database for Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Official Title: An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Study ID: NCT04918186
Conditions
Study Description
Brief Summary: This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
Detailed Description: This study is being conducted to determine if this approach is better or worse than the standard of care for ovarian cancer. The standard of care is defined as care most people get for ovarian cancer.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
The University of Chicago Medical Center, Chicago, Illinois, United States
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Odette Cancer Centre, Toronto, Ontario, Canada
University Health Network, Toronto, Ontario, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
The Jewish General Hospital, Montreal, Quebec, Canada
Contact Details
Name: Helen MacKay
Affiliation: Sunnybrook Health Sciences Centre, Toronto, Ontario Canada
Role: STUDY_CHAIR
Name: Anna Tinker
Affiliation: BCCA - Vancouver Cancer Centre, BC Canada
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
